Safety and efficacy of Nonpeghylated Liposomal Doxorubicin (Myocet) in R-CHOP for the treatment of non Hodgkin's lymphoma in patients with high risk cardiac disease

Trial Profile

Safety and efficacy of Nonpeghylated Liposomal Doxorubicin (Myocet) in R-CHOP for the treatment of non Hodgkin's lymphoma in patients with high risk cardiac disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Prednisone; Rituximab; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Sep 2016 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top